www.fdanews.com/articles/83090-pain-therapeutics-ends-development-of-bowel-drug
PAIN THERAPEUTICS ENDS DEVELOPMENT OF BOWEL DRUG
December 13, 2005
Pain Therapeutics Inc. (PTIE.O: Quote, Profile, Research) said on Friday it will discontinue development of its experimental treatment for irritable bowel syndrome after a pivotal-stage trial failed to show that the drug is effective. The company said a Phase III trial of the drug, known as PTI-901, showed meaningful relief of symptoms in the second month of treatment, but the drug did not demonstrate a meaningful benefit in the third month of treatment, which was the trial's primary goal.